NEW YORK, March 8, 2017 /PRNewswire/ --
On Tuesday, March 07, 2017, the NASDAQ Composite,the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Six out of nine sectors ended Tuesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed
Cambridge, Massachusetts headquartered bluebird bio Inc.'s stock finished Tuesday's session 1.44% lower at $82.30 with a total volume of 774,955 shares traded. Over the last one month and the previous three months, bluebird bio's shares have advanced 4.64% and 17.99%, respectively. Furthermore, the stock has surged 49.31% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 13.63% and 38.36%, respectively. Shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington, have a Relative Strength Index (RSI) of 54.97.
On February 27th, 2017, research firm Maxim Group downgraded the Company's stock rating from 'Buy' to 'Hold'. See our free and comprehensive research report on BLUE at:
The Woodlands, Texas-based Opexa Therapeutics Inc.'s stock fell 2.91%, to close the day at $0.91. The stock recorded a trading volume of 40,756 shares. Opexa Therapeutics' shares are trading 7.64% and 64.08% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops personalized immunotherapy to treat multiple sclerosis and other autoimmune diseases based on its proprietary T-cell technology, have an RSI of 40.49. OPXA free research report PDF is just a click away at:
On Tuesday, shares in Cambridge, Massachusetts headquartered Agios Pharmaceuticals Inc. ended the session 0.72% lower at $49.57 with a total volume of 360,086 shares traded. Agios Pharma's shares have gained 12.92% in the last one month and 3.88% in the previous one year. The stock is trading 10.52% above its 50-day moving average and 3.67% above its 200-day moving average. Moreover, shares of the Company, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, have an RSI of 54.24. Sign up for your complimentary report on AGIO at:
On Tuesday, shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc. recorded a trading volume of 1.11 million shares, which was higher than their three months average volume of 962,790 shares. The stock ended the day 2.84% lower at $9.93. PTC Therapeutics' stock has surged 53.24% in the past one year. The Company is trading above its 200-day moving average by 0.59%. Furthermore, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have an RSI of 31.54.
On March 03rd, 2017, research firm Barclays downgraded the Company's stock rating from 'Overweight' to 'Equal Weight' while revising its previous target price from $20 a share to $13 a share. Register for free on Stock-Callers.com and download the latest research report on PTCT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Blood groups are of four important types determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All